Compare · APLM vs NVO
APLM vs NVO
Side-by-side comparison of Apollomics Inc. (APLM) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both APLM and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $192.84B, about 5018.5x APLM ($38.4M).
- Over the past year, APLM is up 104.1% and NVO is down 41.5% - APLM leads by 145.6 points.
- APLM has been more active in the news (8 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 0 for APLM).
- Company
- Apollomics Inc.
- Novo Nordisk A/S
- Price
- $13.37-3.05%
- $43.19-0.75%
- Market cap
- $38.4M
- $192.84B
- 1M return
- +2.77%
- -2.46%
- 1Y return
- +104.12%
- -41.47%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 8
- 4
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest APLM
- Chief Financial Officer Lin Peter Kuan-How converted options into 10,000 units of CLASS A ORDINARY SHARES and covered exercise/tax liability with 3,588 units of CLASS A ORDINARY SHARES, increasing direct ownership by 40% to 22,312 units (SEC Form 4)
- Chief Executive Officer Chen Hung-Wen converted options into 5,000 units of CLASS A ORDINARY SHARES, increasing direct ownership by 3% to 148,334 units (SEC Form 4)
- Director Chu Yi-An converted options into 500 units of CLASS A ORDINARY SHARES, increasing direct ownership by 50% to 1,500 units (SEC Form 4)
- Director Chen Hong-Jung converted options into 500 units of CLASS A ORDINARY SHARES, increasing direct ownership by 16% to 3,620 units (SEC Form 4)
- Director Tsai Hsien-Shu converted options into 500 units of CLASS A ORDINARY SHARES, increasing direct ownership by 50% to 1,500 units (SEC Form 4)
- Chief Operating Officer Chen Yi-Kuei converted options into 5,000 units of CLASS A ORDINARY SHARES, increasing direct ownership by 50% to 15,000 units (SEC Form 4)
- Director Jan Chen-Huan converted options into 500 units of CLASS A ORDINARY SHARES, increasing direct ownership by 50% to 1,500 units (SEC Form 4)
- SEC Form EFFECT filed by Apollomics Inc.
- Director Huang Ya-Chi converted options into 500 units of CLASS A ORDINARY SHARES, increasing direct ownership by 100% to 1,000 units (SEC Form 4)
- Amendment: SEC Form F-3/A filed by Apollomics Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S